510(k) Report

510(k) · Cleared

Cleared

Aeskulisa Ana Hep-2, Ref 30-7115US

K081104510(k) TraditionalCleared May 2, 200814-day reviewClass II21 CFR 866.5100

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Aesku Diagnostics · LKJ Antinuclear Antibody, Antigen, Control

Cleared on May 2, 2008 after a 14-day review. FDA’s file for it is a 510(k) statement, which names no predicate. 2 later devices descend from it.

Decided
May 2, 2008
Review
14 days
Class
Class II
Product code
LKJ
Recalls
None
Predicates
0

2 later devices descend from it, 2 citing it directly.

Descendants, by year cleared 2013: 2 descendants cleared20052010201520202025
  1. This deviceK081104 Aeskulisa Ana Hep-2, Ref 30-7115USAesku Diagnostics · 2008
  2. Descendant · cites it directly · 0 of its ownK131185 Ana Screen Elisa (Igg)Euroimmun US · 2013
  3. Descendant · cites it directly · 0 of its ownK112996 Euroimmun Anti-Ena Pool Elisa (Igg)Euroimmun US · 2013

Most influential descendants

Showing 2 of 2 · See all
  • K131185Ana Screen Elisa (Igg)Euroimmun US · 2013 · cites it directly0descendants
  • K112996Euroimmun Anti-Ena Pool Elisa (Igg)Euroimmun US · 2013 · cites it directly0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
0 (this device)K081104Aeskulisa Ana Hep-2, Ref 30-7115USAesku Diagnostics2008—
+1K131185Ana Screen Elisa (Igg)Euroimmun US2013—
+1K112996Euroimmun Anti-Ena Pool Elisa (Igg)Euroimmun US2013—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
201320
FIG. 1 — Lineage of K081104, 2008–2013Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA 510(k) statement (indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in LKJ? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new LKJ device

  1. #1 K210902 EliA Ro52, EliA Ro60score 4.0 · 2 generations · no Class I recall
Get a 510(k) Report

What was it cleared against?

FDA’s file for it is a 510(k) statement, which names no predicate.

What descends from it? (2)

2 later devices cite it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K131185Ana Screen Elisa (Igg)Euroimmun US20130
K112996Euroimmun Anti-Ena Pool Elisa (Igg)Euroimmun US20130

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Of its descendants, K131185 (Euroimmun US, 2013) has gone furthest, with 0 descendants of its own.

How does its category compare?

All LKJ devices

LKJ Antinuclear Antibody, Antigen, Control: FDA decisions, review times, recalls and adverse event reports over 20 years. 2008, this device’s year, is highlighted.

FDA decisions per year · LKJ

1in 2022

2008: 12009: 12012: 12022: 1
2007high 1 (2008) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · LKJ

Too few LKJ 510(k)s in any year since 2007 to give a median.

Recalls per year · LKJ

1in 2019

2007: 12010: 72015: 12017: 12019: 1
2007high 7 (2010) · low 0 (2008)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · LKJ

2in 2018

2010: 22011: 172017: 22018: 2
2007high 17 (2011) · low 0 (2007)2025

MAUDE reports naming product code LKJ, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—10
20081—00
20091—00
20100—72
20110—017
20121—00
20130—00
20140—00
20150—10
20160—00
20170—12
20180—02
20190—10
20200—00
20210—00
20221—00
20230—00
20240—00
20250—00
20260—0—

What is it indicated for?

AESKUUSA ANA-HEp2 is a solid phase enzyme immunoassay for the combined qualitative detection of IgG antibodies against HEp2 cells in human serum. Each well is coated with lysed HEp2 cells and specific antigens. The test collectively detects, in one well, total ANAs against double stranded DNA (dsDNA), histones, SS-A (Ro), SS-B (La), Sm, snRNP/Sm, Scl-70, Jo-1 and centromeric antigens along with sera positive for HEp2 immunofluorescence test (IFT).

The assay is a tool in the diagnosis of certain systemic rheumatic diseases and should be used in conjunction with other serological tests and clinical findings.

Indications for use as stated in the FDA 510(k) statement.

Cite this page

510(k) Report. “K081104: Aeskulisa Ana Hep-2, Ref 30-7115US.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/K081104

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026